Tags

Type your tag names separated by a space and hit enter

Oral delivery of lipid-encapsulated Mycobacterium bovis BCG extends survival of the bacillus in vivo and induces a long-term protective immune response against tuberculosis.
Vaccine 2006; 24(12):2071-8V

Abstract

The success of oral-route vaccination using Mycobacterium bovis bacille Calmette-Guérin (BCG) relies on delivery of live, actively metabolising bacilli to confer protection. Here, we describe that lipid-microencapsulation can extend the in vivo survival of bacilli when fed to mice, and can induce a long-lasting protective immune response. Feeding mice with lipid-encapsulated BCG (L-BCG) resulted in greater recovery of viable BCG bacilli from the mesenteric lymph nodes (MLN) compared to mice fed non-encapsulated BCG. A time-course study indicated persistence of viable BCG bacilli in MLN up to 30 weeks post-vaccination, similar to the duration of viable BCG recovery from the spleen following subcutaneous vaccination. The persistence of viable bacilli in the MLN of L-BCG mice invoked long-lasting systemic cell-mediated immune reactivity, with responses similar to those observed in subcutaneously-vaccinated mice. Further, L-BCG-vaccinated mice showed a high degree of protection against aerogenic challenge with virulent M. bovis at 30 weeks post-vaccination, with significant reductions in lung and spleen pathogen burdens. This study identifies that lipid-encapsulation of live BCG bacilli can facilitate increased in vivo survival and immunogenicity of the vaccine in orally-vaccinated mice, and highlights protection via this route for up to 7 months post-immunisation.

Authors+Show Affiliations

Department of Microbiology & Immunology, University of Otago, P.O. Box 56, Dunedin, New Zealand. frank.aldwell@stonebow.otago.ac.nzNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16332403

Citation

Aldwell, F E., et al. "Oral Delivery of Lipid-encapsulated Mycobacterium Bovis BCG Extends Survival of the Bacillus in Vivo and Induces a Long-term Protective Immune Response Against Tuberculosis." Vaccine, vol. 24, no. 12, 2006, pp. 2071-8.
Aldwell FE, Cross ML, Fitzpatrick CE, et al. Oral delivery of lipid-encapsulated Mycobacterium bovis BCG extends survival of the bacillus in vivo and induces a long-term protective immune response against tuberculosis. Vaccine. 2006;24(12):2071-8.
Aldwell, F. E., Cross, M. L., Fitzpatrick, C. E., Lambeth, M. R., de Lisle, G. W., & Buddle, B. M. (2006). Oral delivery of lipid-encapsulated Mycobacterium bovis BCG extends survival of the bacillus in vivo and induces a long-term protective immune response against tuberculosis. Vaccine, 24(12), pp. 2071-8.
Aldwell FE, et al. Oral Delivery of Lipid-encapsulated Mycobacterium Bovis BCG Extends Survival of the Bacillus in Vivo and Induces a Long-term Protective Immune Response Against Tuberculosis. Vaccine. 2006 Mar 15;24(12):2071-8. PubMed PMID: 16332403.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Oral delivery of lipid-encapsulated Mycobacterium bovis BCG extends survival of the bacillus in vivo and induces a long-term protective immune response against tuberculosis. AU - Aldwell,F E, AU - Cross,M L, AU - Fitzpatrick,C E, AU - Lambeth,M R, AU - de Lisle,G W, AU - Buddle,B M, Y1 - 2005/11/21/ PY - 2005/06/02/received PY - 2005/10/17/revised PY - 2005/11/10/accepted PY - 2005/12/8/pubmed PY - 2006/6/29/medline PY - 2005/12/8/entrez SP - 2071 EP - 8 JF - Vaccine JO - Vaccine VL - 24 IS - 12 N2 - The success of oral-route vaccination using Mycobacterium bovis bacille Calmette-Guérin (BCG) relies on delivery of live, actively metabolising bacilli to confer protection. Here, we describe that lipid-microencapsulation can extend the in vivo survival of bacilli when fed to mice, and can induce a long-lasting protective immune response. Feeding mice with lipid-encapsulated BCG (L-BCG) resulted in greater recovery of viable BCG bacilli from the mesenteric lymph nodes (MLN) compared to mice fed non-encapsulated BCG. A time-course study indicated persistence of viable BCG bacilli in MLN up to 30 weeks post-vaccination, similar to the duration of viable BCG recovery from the spleen following subcutaneous vaccination. The persistence of viable bacilli in the MLN of L-BCG mice invoked long-lasting systemic cell-mediated immune reactivity, with responses similar to those observed in subcutaneously-vaccinated mice. Further, L-BCG-vaccinated mice showed a high degree of protection against aerogenic challenge with virulent M. bovis at 30 weeks post-vaccination, with significant reductions in lung and spleen pathogen burdens. This study identifies that lipid-encapsulation of live BCG bacilli can facilitate increased in vivo survival and immunogenicity of the vaccine in orally-vaccinated mice, and highlights protection via this route for up to 7 months post-immunisation. SN - 0264-410X UR - https://www.unboundmedicine.com/medline/citation/16332403/Oral_delivery_of_lipid_encapsulated_Mycobacterium_bovis_BCG_extends_survival_of_the_bacillus_in_vivo_and_induces_a_long_term_protective_immune_response_against_tuberculosis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(05)01161-8 DB - PRIME DP - Unbound Medicine ER -